Genital Diseases, Female  >>  veliparib (ABT-888)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
veliparib (ABT-888) / AbbVie
NCT01113957 / 2009-015082-31: A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer

Completed
2
168
US, Canada, Europe, RoW
ABT-888, ABT-888, veliparib, pegylated liposomal doxorubicin, doxil/caelyx, temozolomide, temozolomide, temodar/temodal
AbbVie (prior sponsor, Abbott)
Ovarian Cancer
06/13
06/13
NCT01306032: Phase II ABT-888 With Cyclophosphamide

Checkmark P2 data-ASCO
Jun 2012 - Jun 2012: P2 data-ASCO
Completed
2
124
US, Canada
ABT-888, Veliparib, Cyclophosphamide, Cytoxan
National Cancer Institute (NCI)
Ovarian Cancer, Primary Peritoneal Cancer, Serous Carcinoma Cancer, Triple-Negative Breast Cancer, Fallopian Tube Cancer
12/14
12/16
NCT01690598 / 2012-001661-32: Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status

Completed
1/2
22
Europe
Veliparib, Topotecan
Vejle Hospital, Abbott
Ovarian Cancer
01/15
02/15
Veli-BRCA, NCT01472783 / 2011-002099-18: Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Completed
1/2
49
Europe
Veliparib
Vejle Hospital, Abbott
Recurrent, Epithelial Ovarian Cancer
01/16
08/16

Download Options